PanTheryx Technology

Medical Nutrition Platform

PanTheryx is redefining the continuum of care for addressing serious GI-related health conditions by researching and developing safe, naturally derived, nutrient-based medical foods and foods for special dietary use.

PanTheryx Technology

Medical Nutrition Platform

PanTheryx is redefining the continuum of care for addressing serious GI-related health conditions by researching and developing safe, naturally derived, nutrient-based medical foods and foods for special dietary use.

Foods for Special Dietary Use

Food used for supplying particular dietary needs due to disease, physical or physiological condition, age, or weight.

Medical Foods

Administered under the supervision of a physician, intended for the specific dietary management of a disease or condition for which there are distinctive nutritional requirements.

Using our medical nutritional platform, we develop these interventions by utilizing macronutrients, micronutrients, and naturally occurring immune factors that work with the body to rapidly restore intestinal health:

The medical nutrition products we develop are formulated to be efficacious, cost-effective, and safe — even for children, the elderly, and other vulnerable populations.

DiaResQ®: A Case Study of a Safe and Effective Medical Nutrition Product

Our first medical nutrition product, DiaResQ®, is a food for special dietary use specially formulated to provide beneficial nutrients for people with diarrhea.

The nutritional deficiencies and malnutrition resulting from diarrhea have been extensively researched, are well-established and understood by the medical community. DiaResQ has been shown in open-label and double blind placebo controlled clinical trials to be effective in providing beneficial nutrients for children and adults with diarrhea, which results in the restoration of intestinal health and function.

Efficacy of a Novel Nutritional Product in Acute Childhood Diarrhea in Guatemala:

Secondary and Exploratory Analyses of a Randomized, Double Blind, Placebo Controlled Trial.

Day 1
p-value: .021
Day 2
p-value: .045
Day 3
p-value: .026
Day 7
p-value: .092
Day 1
p-value: .021
Day 2
p-value: .045
Day 3
p-value: .026
Day 7
p-value: .092
A Comparative Study on the Efficacy of Colostrum and Whole Egg Blend Dietary Supplementation with Standard Therapy versus Standard Therapy Alone In the Management of Acute Watery Non-bloody Diarrhea In Children Aged 1 to 5

A total of 128 children aged 1 to 5 years old, both male and female, with acute watery non-bloody diarrhea were included in the study. Half (n=64) were systematically assigned to the control group who received standard therapy, and the other half to the treatment group who received the intervention once daily for three consecutive days.

A significant reduction in stool frequency

The intervention group had less stool frequency per day with average frequency of 3.5 compared to the control group with average frequency of 4.3. This difference was found to be statistically significant (Welch two-sample t-test p value of <0.001 and non-parametric Wilcoxon test p value of <0.001).

A significant increase in stool consistency

The intervention group had better stool consistency scores with an average score of 2.5 compared to the control group with average score of 2.9. This difference was found to be statistically significant (Welch two-sample t-test p value of <0.001 and non-parametric Wilcoxon test p value of <0.001).

Safety of DiaResQ

Safety has been confirmed by open label, randomized clinical trials, and double-blind, placebo controlled trials. No serious adverse events attributable to DiaResQ have been reported.

Recognized as a Leading Healthcare Innovation

DiaResQ was recognized as one of thirty leading healthcare innovations with great promise to transform global health by 2030 and to help accelerate progress toward the United Nations Sustainable Development Goals health targets.

Reimagining Global Health showcases technologies and interventions with great promise to accelerate progress toward solving the world’s most urgent health issues. Produced by PATH, the report is supported by the Bill & Melinda Gates Foundation, the US Agency for International Development (USAID), and the Norwegian Agency for Development Cooperation.

Source: Reimagining Global Health, Innovation Countdown 2030 Initiative

Continued Research

Current research efforts are exploring the potential of our nutrition-based solutions to address the issue of stunting in malnourished children across the globe.

Our research pipeline targets serious GI-related conditions  where our patented medical nutrition platform is most likely to lead to medical foods and other nutritional interventions that are safe and effective in children, adults, and vulnerable populations.